Author

Kevin R. Reyes

Institution: University of California, San Francisco

Observed institution: University of California, San Francisco

OpenAlex ID: A5127832101

Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab

2026 · Kevin R. Reyes, Ryan Zhu, et al. · European Urology Oncology · 2

Longitudinal tumor-informed ctDNA monitoring and clinical outcomes in advanced urothelial carcinoma treated with enfortumab vedotin ± pembrolizumab.

2026 · Adanma Ayanambakkam, Kevin R. Reyes, et al. · Journal of Clinical Oncology · 1

Clinical and genomic predictors of outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin and pembrolizumab (EVP): UNITE study analysis.

2026 · Elise Y. Cai, Li Zhang, et al. · Journal of Clinical Oncology

Concurrent use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients (pts) with advanced urothelial carcinoma (UC) receiving enfortumab vedotin (EV) plus pembrolizumab (P) therapy.

2026 · Steven Neema Seyedin, Mira Semaan, et al. · Journal of Clinical Oncology

Impact of HER2 expression and ERBB2 alterations on clinical outcomes in patients treated with enfortumab vedotin and pembrolizumab (EVP): UNITE study analysis.

2026 · Kevin R. Reyes, Li Zhang, et al. · Journal of Clinical Oncology

Predictive value of early circulating tumor DNA (ctDNA) response in advanced urothelial carcinoma (aUC) treated with enfortumab vedotin plus pembrolizumab (EVP).

2026 · Tanya Jindal, Elise Y. Cai, et al. · Journal of Clinical Oncology

Association of HER2 and NECTIN4 expression with clinical outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin +/- pembrolizumab (EVP).

2026 · Kevin R. Reyes, Chase Allain Shipp, et al. · Journal of Clinical Oncology

Enfortumab vedotin and pembrolizumab (EVP) outcomes in patients (pts) with advanced urothelial carcinoma (aUC) and FGFR3 alterations: UNITE study analysis.

2026 · Elise Y. Cai, Li Zhang, et al. · Journal of Clinical Oncology

Retrospective analysis of treatment responses to enfortumab vedotin combined with pembrolizumab (EVP) based on FGFR2/3 alterations in patients (pts) with advanced urothelial carcinoma (aUC).

2026 · Mamta Parikh, Steven Neema Seyedin, et al. · Journal of Clinical Oncology

Works count: 9

Citation count: 3

H-index: 1

I10-index: